Endoscopic submucosal dissection for superficial nasopharyngeal carcinoma

Early-stage nasopharyngeal cancer is treated by radiotherapy or chemoradiotherapy [1]. Radiotherapy is less toxic than chemoradiotherapy but has a reported failure rate of 15–30%. Endoscopic submucosal dissection (ESD) is a minimally invasive treatment for superficial oropharyngeal and hypopharyngeal cancers [2–4], but it has not been previously performed for nasopharyngeal cancer owing to the difficulty of an endoscopic approach. This case report demonstrates ESD for nasopharyngeal lesions.

A 42-year-old man complained of throat discomfort, and papillary tumors were detected in the nasopharynx and oropharynx by nasopharyngolaryngoscopy. Biopsy specimens obtained from these lesions showed squamous cell papilloma with severe atypia. ESD was planned for total biopsy of these lesions. The patient was transorally intubated and ESD was performed under general anesthesia. A mouth opener was placed and the uvula was pulled with a thread to secure the field of view (▶ Fig. 1). An endoscope with an 8.9-mm diameter tip (GIF-H290; Olympus Corporation, Tokyo, Japan), which cannot be inserted transnasally under sedation, was used. The nasopharyngeal lesions were approached using this scope in the transnasal forward and transoral retroflex views (▶ Fig. 2). En bloc resection was achieved by ESD for all four lesions using an electrosurgical knife (Flushknife 1.5 mm; FUJIFILM Medical Co., Ltd., Tokyo, Japan) (▶ Video 1). He was discharged on postoperative day 4 without any adverse events.

Histologic examinations showed an intraepithelial squamous cell carcinoma for lesion #1 of the posterior wall of the nasopharynx and papilloma for the others (lesions #2 and #3). Follow-up endoscopy 4 months after ESD showed no remnant lesion or stenosis (▶ Fig. 3).

Endoscopy_UCTN_Code_CPL_1AH_2AZ
Competing interests
Takashi Kanesaka has received personal fees from Olympus Corporation. Ryu Ishihara has received personal fees from Olympus Corporation and FUJIFILM Medical Co., Ltd. Other authors have no financial relationships to disclose.

The authors
Hirohisa Sakurai1,2, Takashi Kanesaka1,3, Tadashi Yoshii4, Kosuke Urabe4, Takashi Fujii4, Tomoki Michida1, Ryu Ishihara1
1 Department of Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan
2 Department of Gastroenterology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan
3 Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan
4 Department of Head and Neck Surgery, Osaka International Cancer Institute, Osaka, Japan

References